Drugs.com - Clinical Trials

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease

RICHMOND, Calif.--(BUSINESS WIRE)--Feb. 6, 2025-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...

Feb 9, 2025 - 21:44
 0
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data for Isaralgagene Civaparvovec in Fabry Disease
RICHMOND, Calif.--(BUSINESS WIRE)--Feb. 6, 2025-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene...
Read More

Tags:

Previous Article

Bracco Imaging Receives FDA Fast Track Designation for BR55

Next Article

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation f...

Related Posts

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Trac...

Feb 9, 2025  0

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Mineralys Therapeutics Announces Phase 2 Clinical Trial...

Feb 9, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0